Home > Cardiology > AHA 2021 > CVD Risk Reduction > No significant effect of aspirin on reducing cognitive impairment

No significant effect of aspirin on reducing cognitive impairment

Presented By
Prof. Jane Armitage, Oxford University, UK
Conference
AHA 2021
Trial
ASCEND
Aspirin did not significantly reduce dementia outcomes in patients from the ASCEND trial with diabetes. The results were based on 1,146 dementia events and trended towards a beneficial effect of aspirin, excluding harms >2%. Subgroup analyses could provide insight into the extent to which certain populations may benefit from long-term aspirin use. Prof. Jane Armitage (Oxford University, UK) explained that the effect of aspirin on cognitive impairment could be beneficial by avoiding ischaemic events in the brain [1]. However, there could be a harmful effect of aspirin on cognitive impairment via the increased risk of intracranial bleeding. Prior randomised trials have not observed a clear effect of aspirin on cognitive impairment. In the current analysis, patients with diabetes from the ASCEND trial (NCT00135226; n=15,480; mean age 63 years) were randomise...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on